Four-year follow-up data confirms olverembatinib's long-term efficacy and safety in TKI-resistant CML-CP patients in China and the US

Olverembatinib (耐立克®) demonstrated superior long-term efficacy and safety in a 4-year follow-up study for TKI-resistant CML-CP patients. The study showed a median event-free survival of 21.2 months for耐立克® versus 2.9 months for the control group, with a 7% rate of vascular occlusive events. These findings, presented at the 2025 ASH Annual Meeting, reinforce耐立克®'s significant benefit, including in patients without the T315I mutation.